We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Albemarle (ALB - Free Report) closed at $163.89, marking a -2.45% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 1.52% for the day. On the other hand, the Dow registered a loss of 1.56%, and the technology-centric Nasdaq decreased by 1.78%.
Prior to today's trading, shares of the specialty chemicals company had lost 4.24% was narrower than the Basic Materials sector's loss of 5.1% and lagged the S&P 500's loss of 2.25%.
The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is expected to report EPS of $0.78, up 533.33% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.28 billion, up 18.91% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.15 per share and a revenue of $5.58 billion, indicating changes of +1131.65% and +8.48%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 76.59% upward. Albemarle presently features a Zacks Rank of #1 (Strong Buy).
From a valuation perspective, Albemarle is currently exchanging hands at a Forward P/E ratio of 20.61. This indicates a premium in contrast to its industry's Forward P/E of 16.73.
We can also see that ALB currently has a PEG ratio of 1.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Chemical - Diversified was holding an average PEG ratio of 1.53 at yesterday's closing price.
The Chemical - Diversified industry is part of the Basic Materials sector. At present, this industry carries a Zacks Industry Rank of 174, placing it within the bottom 29% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Declines More Than Market: Some Information for Investors
In the latest trading session, Albemarle (ALB - Free Report) closed at $163.89, marking a -2.45% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 1.52% for the day. On the other hand, the Dow registered a loss of 1.56%, and the technology-centric Nasdaq decreased by 1.78%.
Prior to today's trading, shares of the specialty chemicals company had lost 4.24% was narrower than the Basic Materials sector's loss of 5.1% and lagged the S&P 500's loss of 2.25%.
The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is expected to report EPS of $0.78, up 533.33% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.28 billion, up 18.91% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.15 per share and a revenue of $5.58 billion, indicating changes of +1131.65% and +8.48%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 76.59% upward. Albemarle presently features a Zacks Rank of #1 (Strong Buy).
From a valuation perspective, Albemarle is currently exchanging hands at a Forward P/E ratio of 20.61. This indicates a premium in contrast to its industry's Forward P/E of 16.73.
We can also see that ALB currently has a PEG ratio of 1.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Chemical - Diversified was holding an average PEG ratio of 1.53 at yesterday's closing price.
The Chemical - Diversified industry is part of the Basic Materials sector. At present, this industry carries a Zacks Industry Rank of 174, placing it within the bottom 29% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.